A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
T cell immunity directed against tumor-encoded amino acid substitutions occurs in some melanoma patients. This implicates missense mutations as a source of patient-specific neoantigens. However, a systematic evaluation of these putative neoantigens as targets of antitumor immunity is lacking. Moreover, it remains unknown whether vaccination can augment such responses. We found that a dendritic cell vaccine led to an increase in naturally occurring neoantigen-specific immunity and revealed previously undetected human leukocyte antigen (HLA) class I-restricted neoantigens in patients with advanced melanoma. The presentation of neoantigens by HLA-A*02:01 in human melanoma was confirmed by mass spectrometry. Vaccination promoted a diverse neoantigen-specific T cell receptor (TCR) repertoire in terms of both TCR-β usage and clonal composition. Our results demonstrate that vaccination directed at tumor-encoded amino acid substitutions broadens the antigenic breadth and clonal diversity of antitumor immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Vaccines have been used as an approach to enhance anti-tumor immune responses and have demonstrated encouraging results in preclinical and clinical studies, leading to an expansion of the intratumoral T cell infiltration and anti-tumor immune responses (Carreno et al., 2015; Ott et al., 2017).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Carreno et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Flicek, P., Amode, M. R., Barrell, D., Beal, K., Billis, K., Brent, S., Carvalho-Silva, D., Clapham, P., Coates, G., Fitzgerald, S., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1196 · Cited by 1,214
A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.-H., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,154
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Coulie, P. G., Van den Eynde, B. J., van der Bruggen, P., & Boon, T. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3670 · Cited by 1,138
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,111
Reliable prediction of T‐cell epitopes using neural networks with novel sequence representations
Nielsen, M., Lundegaard, C., Worning, P., Lauemøller, S. L., Lamberth, K., Buus, S., Brunak, S., & Lund, O. (2003) · Protein Science · doi:10.1110/ps.0239403 · Cited by 1,074
Robbins, P. F., Lu, Y.-C., El-Gamil, M., Li, Y. F., Gross, C., Gartner, J., Lin, J. C., Teer, J. K., Cliften, P., Tycksen, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3161 · Cited by 1,072
Cited by
Items 501–600 of 1,003
Neoantigen discovery and applications in glioblastoma: An immunotherapy perspective
Wang, C., Yu, M., & Zhang, W. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215945 · Cited by 43
Schrörs, B., Lübcke, S., Lennerz, V., Fatho, M., Bicker, A., Wölfel, C., Derigs, P., Hankeln, T., Schadendorf, D., Paschen, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16048 · Cited by 43
MHC II immunogenicity shapes the neoepitope landscape in human tumors
Kim, J. Y., Cha, H., Kim, K., Sung, C., An, J., Bang, H., Kim, H., Yang, J. O., Chang, S., Shin, I., et al. (2023) · Nature Genetics · doi:10.1038/s41588-022-01273-y · Cited by 42
Nagaoka, K., Hosoi, A., Iino, T., Morishita, Y., Matsushita, H., & Kakimi, K. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1395124 · Cited by 42
Li, X., Shenashen, M. A., Wang, X., Ito, A., Taniguchi, A., & El‐Safty, S. A. (2017) · Scientific Reports · doi:10.1038/s41598-017-12446-9 · Cited by 42
Zhang, L., Huang, J., Chen, X., Pan, C., He, Y., Su, R., Guo, D., Yin, S., Wang, S., Zhou, L., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003132 · Cited by 42
An mRNA vaccine elicits STING-dependent antitumor immune responses
Chen, Z., Meng, C., Mai, J., Liu, Y., Li, H., & Shen, H. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.11.013 · Cited by 42
Johanns, T. M., Bowman-Kirigin, J. A., Liu, C. J., & Dunn, G. P. (2017) · Neurosurgery · doi:10.1093/neuros/nyx321 · Cited by 41
Genomic Alteration Burden in Advanced Prostate Cancer and Therapeutic Implications
Ryan, M. J., & Bose, R. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01287 · Cited by 41
Olsen, H. E., Lynn, G. M., Valdes, P. A., Cerecedo-Lopez, C. D., Ishizuka, A. S., Arnaout, O. M., Bi, W. L., Peruzzi, P. P., Chiocca, E. A., Friedman, G. K., et al. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab027 · Cited by 41
Identification and Targeting of Mutant Peptide Neoantigens in Cancer Immunotherapy
Verdon, D. J., & Jenkins, M. R. (2021) · Cancers · doi:10.3390/cancers13164245 · Cited by 42
Recent advances in exosome-based immunotherapy applied to cancer
Xie, J., Zheng, Z., Tuo, L., Deng, X., Tang, H., Peng, C., & Zou, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1296857 · Cited by 40
Challenges and solutions for therapeutic TCR ‐based agents
Malviya, M., Aretz, Z. E. H., Molvi, Z., Lee, J., Pierre, S. A., Wallisch, P., Dao, T., & Scheinberg, D. A. (2023) · Immunological Reviews · doi:10.1111/imr.13233 · Cited by 40
Chen, B., Huang, R., Zeng, W., Wang, W., & Min, Y. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122434 · Cited by 40
Neoantigen Cancer Vaccines: Generation, Optimization, and Therapeutic Targeting Strategies
Reynolds, C. R., Tran, S., Jain, M., & Narendran, A. (2022) · Vaccines · doi:10.3390/vaccines10020196 · Cited by 40
Challenges targeting cancer neoantigens in 2021: a systematic literature review
Chen, I., Chen, M. Y., Goedegebuure, S. P., & Gillanders, W. E. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1935248 · Cited by 39
Lipid nanoparticles: a promising tool for nucleic acid delivery in cancer immunotherapy
Abaza, T., Mohamed, E., & Zaky, M. Y. (2025) · Medical Oncology · doi:10.1007/s12032-025-02939-3 · Cited by 39
Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies
Tubb, V., Schrikkema, D. S., Croft, N. P., Purcell, A. W., Linnemann, C., Freriks, M. R., Chen, F. E., Long, H. M., Lee, S. P., & Bendle, G. M. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0386-y · Cited by 39
Innovative strategies to advance CAR T cell therapy for solid tumors.
Huang, M., Jinniu, D., Gao, L., & Zhou, J. (2020) · PubMed Central · Cited by 39
Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan/JQ1 for chemo-immunotherapy
He, Z., Zhang, M., Wang, Y., He, Y., Wang, H.-R., Chen, B., Tu, B., Zhu, S., & Huang, Y. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00570-8 · Cited by 39
Kong, F., Chen, T., Li, X., & Jia, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.737674 · Cited by 39
Neoadjuvant therapy alters the immune microenvironment in pancreatic cancer
Zhang, H., Ye, L., Yu, X., Jin, K., & Wu, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.956984 · Cited by 39
Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors
Bear, A. S., Nadler, R. B., O’Hara, M. H., Stanton, K. L., Xu, C. B., Saporito, R., Rech, A. J., Baroja, M. L., Blanchard, T., Elliott, M. H., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci175790 · Cited by 38
Self-citationNew emerging targets in cancer immunotherapy: the role of neoantigens
Mattos‐Arruda, L. D., Blanco-Heredia, J., Aguilar‐Gurrieri, C., Carrillo, J., & Blanco, J. (2019) · ESMO Open · doi:10.1136/esmoopen-2020-000684 · Cited by 38
Development of neoantigens: from identification in cancer cells to application in cancer vaccines
Ebrahimi, N., Akbari, M., Ghanaatian, M., moghaddam, P. R., Adelian, S., Boroujeni, M. B., Yazdani, E., Ahmadi, A., & Hamblin, M. R. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1951246 · Cited by 38
Peri, A., Greenstein, E., Alon, M., Pai, J. A., Dingjan, T., Reich-Zeliger, S., Barnea, E., Barbolin, C., Levy, R., Arnedo-Pac, C., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci129466 · Cited by 38
Proteogenomics meets cancer immunology: mass spectrometric discovery and analysis of neoantigens
Polyakova, A., Kuznetsova, K. G., & Moshkovskii, S. A. (2015) · Expert Review of Proteomics · doi:10.1586/14789450.2015.1070100 · Cited by 37
Shen, H., Sun, T., Hoang, H. H., Burchfield, J. S., Hamilton, G. F., Mittendorf, E. A., & Ferrari, M. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.09.002 · Cited by 37
Next Generation Cancer Vaccines—Make It Personal!
Terbuch, A., & Lopez, J. S. (2018) · Vaccines · doi:10.3390/vaccines6030052 · Cited by 37
Transcutaneous delivery of DNA/mRNA for cancer therapeutic vaccination
Sun, X., Zeng, L., & Huang, Y. (2019) · The Journal of Gene Medicine · doi:10.1002/jgm.3089 · Cited by 37
NeoPeptide: an immunoinformatic database of T-cell-defined neoantigens
Zhou, W., Qu, Z. Y., Song, C.-Y., Sun, Y., Lai, A., Luo, M., Ying, Y.-Z., Meng, H., Zhao, L., He, Y., et al. (2019) · Database · doi:10.1093/database/baz128 · Cited by 37
Multimodal stratified imaging of nanovaccines in lymph nodes for improving cancer immunotherapy
Tian, R., Ke, C., Rao, L., Lau, J., & Chen, X. S. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.08.009 · Cited by 37
Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects
Zhong, C. F., Li, Y., Yang, J., Jin, S., Chen, G., Li, D., Fan, X., & Lin, H. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.589680 · Cited by 37
Nam, J., Son, S., Park, K. S., & Moon, J. J. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100093 · Cited by 37
Machine Learning Approaches to TCR Repertoire Analysis
Katayama, Y., Yokota, R., Akiyama, T., & Kobayashi, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.858057 · Cited by 37
Sánchez-León, M. L., Jiménez‐Cortegana, C., Cabrera, G., Vermeulen, E. M., de la Cruz‐Merino, L., & Sánchez‐Margalet, V. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1050484 · Cited by 37
Tumor neoantigens: Novel strategies for application of cancer immunotherapy
Guan, H., Wu, Y., Li, L., Yang, Y., Qiu, S., Zhao, Z., Chu, X., He, J., Chen, Z., ZHANG, Y., et al. (2023) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.029924 · Cited by 37
Advances in Cancer Vaccine Research
Liu, N., Xiao, X., Zhang, Z.-Q., Mao, C., Wan, M., & Shen, J. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c01154 · Cited by 37
Dharmadhikari, B., Nickles, E. P., Harfuddin, Z., Ishak, N. D. B., Zeng, Q., Bertoletti, A., & Schwarz, H. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2144-x · Cited by 37
neoepiscope improves neoepitope prediction with multivariant phasing
Wood, M. A., Nguyen, A., Struck, A. J., Ellrott, K., Nellore, A., & Thompson, R. F. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz653 · Cited by 37
Hirama, T., Tokita, S., Nakatsugawa, M., Murata, K., Nannya, Y., Matsuo, K., Inoko, H., Hirohashi, Y., Hashimoto, S., Ogawa, S., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.146356 · Cited by 37
New challenges in therapeutic vaccines against HIV infection
Leal, L., Lucero, C., Gatell, J. M., Gallart, T., Plana, M., & García, F. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1322513 · Cited by 37
Population-level distribution and putative immunogenicity of cancer neoepitopes
Wood, M. A., Paralkar, M., Paralkar, M. P., Nguyen, A., Struck, A. J., Ellrott, K., Margolin, A. A., Nellore, A., & Thompson, R. F. (2018) · BMC Cancer · doi:10.1186/s12885-018-4325-6 · Cited by 36
Jiang, T., Su, C., Cheng, R., Pan, Y., Zhang, H., He, J., He, Y., Tang, R., Ren, S., & Zhou, C. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.03.03 · Cited by 36
Systematically Characterizing A-to-I RNA Editing Neoantigens in Cancer
Zhou, C., Wei, Z., Zhang, L., Yang, Z., & Liu, Q. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.593989 · Cited by 36
Synergistic Activation of Antitumor Immunity by a Particulate Therapeutic Vaccine
Mai, J., Li, Z., Xia, X., Zhang, J., Li, J., Liu, H., Shen, J., Ramirez, M., Li, F., Li, Z., et al. (2021) · Advanced Science · doi:10.1002/advs.202100166 · Cited by 36
The Role of Neoantigens in Cancer Immunotherapy
Zhu, Y., & Liu, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682325 · Cited by 36
Neoantigens as potential vaccines in hepatocellular carcinoma
Repáraz, D., Ruiz, M., Llópiz, D., Silva, L., Vercher, E., Aparicio, B., Egea, J., Tamayo, I., Hervás‐Stubbs, S., García-Balduz, J., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003978 · Cited by 36
Neoantigen-directed therapeutics in the clinic: where are we?
Lybaert, L., Thielemans, K., Feldman, S. A., van der Burg, S. H., Bogaert, C., & Ott, P. A. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.02.004 · Cited by 36
T-cell target antigens across major gynecologic cancers
Rodríguez-García, A., Minutolo, N. G., Robinson, J. M., & Powell, D. J. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.03.510 · Cited by 36
Chung, D. J., Carvajal, R. D., Postow, M. A., Sharma, S., Pronschinske, K. B., Shyer, J. A., Singh-Kandah, S. V., Dickson, M. A., D’Angelo, S. P., Wolchok, J. D., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1372081 · Cited by 36
Melanoma vaccines: clinical status and immune endpoints
Maurer, D. M., Butterfield, L. H., & Vujanovic, L. N. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000535 · Cited by 36
Automated Flow Synthesis of Tumor Neoantigen Peptides for Personalized Immunotherapy
Truex, N. L., Holden, R. L., Wang, B.-Y., Chen, P.-G., Hanna, S., Hu, Z., Shetty, K., Olive, O., Neuberg, D., Hacohen, N., et al. (2020) · Scientific Reports · doi:10.1038/s41598-019-56943-5 · Cited by 33
Miller, A. M., Koşaloğlu‐Yalçın, Z., Westernberg, L., Montero, L., Bahmanof, M., Frentzen, A., Lanka, M., Premlal, A. L. R., Seumois, G., Greenbaum, J., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.abj9905 · Cited by 35
Strategy and clinical application of up-regulating cross presentation by DCs in anti-tumor therapy
Lu, Y., Shi, Y., & You, J. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.11.011 · Cited by 35
Antigen discovery for the development of cancer immunotherapy
Ahn, R., Cui, Y., & White, F. M. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101733 · Cited by 35
Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer
Baleeiro, R. B., Liu, P., Chard, L. S., Gioia, C. D., Nagano, A., Cutmore, L. C., Wang, J., Chelala, C., Nyambura, L. W., Walden, P., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007336 · Cited by 35
Lövgren, T., Sarhan, D., Truxová, I., Choudhary, B., Maas, R. R., Melief, J., Nystrom, M. L., Edbäck, U., Vermeij, R., Scurti, G. M., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2029-4 · Cited by 35
Shang, L., Jiang, X., Zhao, X., Huang, X., Wang, X., Jiang, X., Kong, X., Yao, M., Jiang, S., & Wong, P. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101648 · Cited by 35
Karasaki, T., Nagayama, K., Kawashima, M., Hiyama, N., Murayama, T., Kuwano, H., Nitadori, J., Anraku, M., Sato, M., Miyai, M., et al. (2015) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.11.006 · Cited by 34
Novel tools to assist neoepitope targeting in personalized cancer immunotherapy
Saini, S. K., Rekers, N. H., & Hadrup, S. R. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx544 · Cited by 34
Skrombolas, D., Sullivan, M. A., & Frelinger, J. G. (2019) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2018.0129 · Cited by 34
Kwak, M., Leick, K. M., Melssen, M. M., & Slingluff, C. L. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.02.003 · Cited by 34
Xiao, P., Wang, J., Fang, L., Zhao, Z., Sun, X., Liu, X., Cao, H., Zhang, P., Wang, D., & Li, Y. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202104068 · Cited by 34
Kwon, O. K., Jeon, J. M., Sung, E., Na, A., Kim, S. J., & Lee, S. (2018) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20086 · Cited by 34
Probst, P., Stringhini, M., Ritz, D., Fugmann, T., & Neri, D. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1728 · Cited by 34
van Dinther, D., Venegas, M. L., Veninga, H., Olesek, K., Hoogterp, L., Revet, M., Ambrosini, M., Kalay, H., Stöckl, J., van Kooyk, Y., et al. (2019) · Cancers · doi:10.3390/cancers11020183 · Cited by 34
NetH2pan: A Computational Tool to Guide MHC Peptide Prediction on Murine Tumors
DeVette, C. I., Andreatta, M., Bardet, W., Cate, S. J., Jurtz, V. I., Jackson, K. W., Welm, A. L., Nielsen, M., & Hildebrand, W. H. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0298 · Cited by 33
Self-citationLee, K. L., Benz, S. C., Hicks, K. C., Nguyen, A., Gameiro, S. R., Palena, C., Sanborn, Z., Su, Z., Ordentlich, P., Rohlin, L., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0620 · Cited by 33
Adoptive Cellular Therapy for Solid Tumors
Bear, A. S., Fraietta, J. A., Narayan, V., O’Hara, M. H., & Haas, N. B. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_321115 · Cited by 34
Localized delivery of immunotherapeutics: A rising trend in the field
Wang, J., Zhang, Y., Pi, J., Xing, D., & Wang, C. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.10.013 · Cited by 33
Yu, G., Fan, D., Ge, W., Sun, L., Zhang, L., Yuan, L., Li, N., Dai, H., Shi, L., & Wang, Y. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101498 · Cited by 33
Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia
Purroy, N., & Wu, C. J. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026740 · Cited by 33
Cofano, F., Monticelli, M., Ajello, M., Zenga, F., Marengo, N., Perna, G. D., Altieri, R., Cassoni, P., Bertero, L., Melcarne, A., et al. (2019) · Cancer Control · doi:10.1177/1073274819870549 · Cited by 33
Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma
LoRusso, P. M., Schalper, K. A., & Sosman, J. A. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12847 · Cited by 33
New chimeric antigen receptor design for solid tumors
Wang, Y., Luo, F., Yang, J., Zhao, C., & Chu, Y. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01934 · Cited by 32
Li, Q., Zeng, H., Liu, T., Wang, P., Zhang, R., Zhao, B., Feng, T., Yang, Y., Wu, J., Zheng, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54650-y · Cited by 32
Chao, C.-J., Endong, Z., Trinh, D. N., Udofa, E., Lin, H., Silvers, C., Huo, J., He, S., Zheng, J., Cai, X., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59840-w · Cited by 32
A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations
Toor, J. S., Rao, A. A., McShan, A. C., Yarmarkovich, M., Nerli, S., Yamaguchi, K., Madejska, A. A., Nguyen, S., Tripathi, S. M., Maris, J. M., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00099 · Cited by 32
Macfarlane, F. R., Lorenzi, T., & Chaplain, M. A. J. (2018) · Bulletin of Mathematical Biology · doi:10.1007/s11538-018-0412-8 · Cited by 32
Impact of checkpoint blockade on cancer vaccine–activated CD8+ T cell responses
Santos, P. M. L., Adamik, J., Howes, T. R., Du, S. W., Vujanovic, L. N., Warren, S. E., Gambotto, A. A., Kirkwood, J. M., & Butterfield, L. H. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20191369 · Cited by 32
The Ways of Isolating Neoantigen-Specific T Cells
Li, Q., & Ding, Z. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01347 · Cited by 32
Personal Neoantigen Cancer Vaccines: A Road Not Fully Paved
Fritsch, E. F., Burkhardt, U. E., Hacohen, N., & Wu, C. J. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0526 · Cited by 32
Neoantigens and their potential applications in tumor immunotherapy (Review)
Fang, X., Guo, Z., Liang, J., Wen, J., Liu, Y., Guan, X., & Hong, L. (2022) · Oncology Letters · doi:10.3892/ol.2022.13208 · Cited by 32
What’s next for cancer vaccines
Adamik, J., & Butterfield, L. H. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo4632 · Cited by 32
Truxová, I., Hensler, M., Škapa, P., Halaška, M. J., Laco, J., Ryška, A., Spisek, R., & Fucikova, J. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.09.003 · Cited by 32
Radiation therapy and the innate immune response: Clinical implications for immunotherapy approaches
Gómez, V., Mustapha, R., Ng, K., & Ng, T. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14351 · Cited by 32
Pandey, S., Gruenbaum, A., Kanashova, T., Mertins, P., Cluzel, P., & Chevrier, N. (2020) · Cell Systems · doi:10.1016/j.cels.2020.10.001 · Cited by 32
Liu, K., Chao, T.-Y., Chang, J., Cheng, A., Ch’ang, H.-J., Kao, W., Wu, Y.-C., Yu, W.-L., Chung, T.-R., & Whang‐Peng, J. (2016) · Journal of Biomedical Science · doi:10.1186/s12929-016-0279-7 · Cited by 32
Antigen targeting to dendritic cells: Still a place in future immunotherapy?
Stoitzner, P., Romani, N., Rademacher, C., Probst, H. C., & Mahnke, K. (2022) · European Journal of Immunology · doi:10.1002/eji.202149515 · Cited by 31
Keshari, S., Shavkunov, A. S., Miao, Q., Saha, A., Minowa, T., Molgora, M., Williams, C. D., Chaib, M., Highsmith, A. M., Pineda, J. E., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114875 · Cited by 31
Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccines
Menez-Jamet, J., Gallou, C., Rougeot, A., & Kosmatopoulos, K. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.05.15 · Cited by 31
Li, F., Chen, C., Ju, T., Gao, J., Yan, J., Wang, P., Xu, Q., Hwu, P., Du, X., & Lizee, G. A. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1238539 · Cited by 31
Precision T-cell therapy targets tumours
Melief, C. J. M. (2017) · Nature · doi:10.1038/nature23093 · Cited by 31
Tumour associated glycans: A route to boost immunotherapy?
Scott, E., Elliott, D. J., & Munkley, J. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.12.015 · Cited by 31
CCL21 Programs Immune Activity in Tumor Microenvironment
Sharma, S. P., Kadam, P., & Dubinett, S. M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-36667-4_7 · Cited by 31
Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC)
Chen, H., Yang, G., Xiao, J., Zheng, L., You, L., & Zhang, T. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.06.011 · Cited by 31
Feeney, O. M., Gracia, G., Brundel, D. H. S., Trevaskis, N. L., Cao, E., Kaminskas, L. M., & Porter, C. J. H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.10.002 · Cited by 31
Dendritic cells: understanding ontogeny, subsets, functions, and their clinical applications
Li, W., Yu, C., Zhang, X., Gu, Y., He, X., Xu, R., Xu, J. F., Yu, G., & Wu, Y. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00300-8 · Cited by 30
Genomic determinants of cancer immunotherapy
Miao, D., & Allen, E. M. V. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.05.010 · Cited by 30
Metadata
- Authors
- Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. A., Ly, A., Lie, W.-R., Hildebrand, W. H., Mardis, E. R., & Linette, G. P.
- Affiliations
- Washington University in St. Louis (US)
- Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
- University of Oklahoma Health Sciences Center (US)
- MilliporeSigma (United States) (US)
- Corresponding author
- Carreno, Beatriz M.
- ORCID
- Venue
- Science
- Published
- 2015-05-15
- Volume
- 348
- Issue
- 6236
- Pages
- 803-808
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4549796
- OpenAlex
- W2007026865
- Cited by
- 1,285
- References
- 37
- Citations by year
- 2026: 45 · 2025: 90 · 2024: 104 · 2023: 108 · 2022: 126 · 2021: 159 · 2020: 135 · 2019: 138 · 2018: 124 · 2017: 118 · 2016: 99 · 2015: 38
- FWCI
- 62.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Human Genome Research Institute (5U54HG00307)
- National Cancer Institute (P30 CA91842, R21 CA179695)
- Barnes-Jewish Hospital Foundation
- Siteman Cancer Frontier Fund
- Our Mark on Melanoma (MOM) Foundation
- Come Out Swinging (COS) Foundation
- Blackout Melanoma Foundation
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- dendritic cell vaccine, melanoma, neoantigens, missense mutations, T cell receptor repertoire, HLA-A*0201, T cell-mediated antitumor immunity, clonal diversity, cancer immunotherapy
- MeSH terms
- Antigens, Neoplasm, Dendritic Cells, Humans, Melanoma, Mutation, Skin Neoplasms, T-Lymphocytes, Monitoring, Immunologic, HLA-A2 Antigen, Immunotherapy, Active, Receptors, Antigen, T-Cell, alpha-beta, Antigen Presentation, Cancer Vaccines, Amino Acid Substitution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.